Mometason Furoát Cipla (Mometasone Furoate Monohydrate)

Mometasone furoate, the active ingredient in Mometason Furoát Cipla, is a corticosteroid presented as an inhalation formulation for inhalation use. It reduces airway inflammation in patients with asthma and chronic obstructive pulmonary disease, helping to improve breathing and prevent exacerbations.

GNH USA supplies Mometason Furoát Cipla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mometason Furoát Cipla is a glucocorticoid inhaler that targets airway inflammation in chronic respiratory diseases.

- Asthma: improves lung function and reduces the frequency of exacerbations. - Chronic obstructive pulmonary disease (COPD): decreases airway inflammation and eases breathing difficulty. - Persistent airway hyperresponsiveness: helps maintain control of symptoms in patients with reversible airway obstruction.

Mometason Furoát Cipla may cause a range of adverse reactions, most of which are related to local exposure of the airways.

Common Side Effects: - Oral thrush (candidiasis): fungal growth in the mouth. - Hoarseness or dysphonia: changes in voice quality. - Cough or throat irritation: mild discomfort after inhalation. - Headache: transient mild pain. - Nasal irritation: dryness or soreness. - Upper respiratory tract infection: mild cold‑like symptoms.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Suppression of adrenal function: signs of cortisol deficiency. - Osteoporosis or bone loss with long‑term high‑dose use. - Glaucoma or cataract formation with prolonged exposure. - Pneumonia: especially in patients with COPD.

Before prescribing Mometason Furoát Cipla, clinicians should consider several safety aspects.

- Monitor for oral thrush: advise patients to rinse mouth after each inhalation. - Assess for signs of adrenal suppression: especially with high‑dose or prolonged therapy. - Use caution in patients with active infections: respiratory or systemic infections may worsen. - Avoid abrupt discontinuation: taper dose to prevent rebound inflammation. - Evaluate bone health: consider calcium and vitamin D supplementation for long‑term users. - Store at ambient temperature: keep below 25 °C, protect from moisture and direct sunlight.

Mometason Furoát Cipla can interact with other medicines that affect systemic corticosteroid exposure or immune function.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, phenytoin): may reduce drug efficacy. - Systemic immunosuppressants (e.g., azathioprine, cyclosporine): increase risk of infection.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may modestly raise systemic levels. - Live vaccines: potential reduced vaccine efficacy. - Diuretics (e.g., furosemide): may increase risk of hypokalemia when systemic absorption occurs. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): monitor for additive gastrointestinal irritation.